The Asia-Pacific artificial intelligence in drug discovery market is rapidly evolving, driven by advancements in deep learning and increased partnerships between pharmaceutical and technology companies. The market was valued at USD 340 million in 2025 and is expected to reach USD 2,890 million by 2035, growing at a CAGR of 21.8% from 2024 to 2035.
The economic impact of tariffs on "Asia-Pacific Artificial Intelligence in Drug Discovery Market".
Market Growth Drivers
Adoption of AI-Driven Drug Discovery Platforms: The increasing demand for precision medicine and the rising need to reduce drug development timelines are driving the adoption of AI-powered platforms. Companies like BenevolentAI and Insilico Medicine are leveraging advanced machine learning and data analytics to accelerate candidate screening and optimize molecule design, leading to higher efficiency and lower R&D costs. Their collaborations with regional pharmaceutical companies have resulted in new drug candidates progressing more rapidly through the discovery pipeline.
Government Initiatives and Increased R&D Investment: Governments across APAC countries like China, Japan, and South Korea are investing in digital healthcare and AI infrastructure, supporting domestic biopharma innovation. For example, China's National Health Commission has launched policies to incorporate AI into healthcare, leading firms like Huawei Cloud and Tencent AI Lab to develop AI solutions tailor-made for drug discovery applications, further spurring market growth.
Market Trends
Collaborative Partnerships Between Pharma and Tech Companies: The Asia-Pacific region is witnessing robust collaborations between traditional pharma companies and AI-technology providers. For instance, Takeda Pharmaceuticals has partnered with Peptilogics to leverage AI-based peptide drug discovery. Such alliances are enhancing drug discovery pipelines, thereby fostering accelerated compound identification and improving clinical trial outcomes.
Expansion of Cloud-Based AI Drug Discovery Solutions: Major cloud service providers, including Google Cloud and Alibaba Cloud, are expanding their footprints in the life sciences vertical by offering scalable AI platforms to APAC-based biotechs. These solutions enable real-time data processing and reduce overhead costs associated with in-house infrastructure, encouraging smaller enterprises to enter the market and fueling competitive innovation.
Market Opportunities
Rising Prevalence of Chronic Diseases: Increasing rates of cancer, diabetes, and other chronic illnesses in Asia-Pacific present an opportunity for AI-driven solutions to streamline discovery of targeted therapeutics. Companies like Deep Intelligent Pharma in China are poised to deliver next-generation drug candidates aimed at region-specific disease profiles.
Emergence of Start-up Ecosystem: The rise of AI-focused biotech startups, particularly in markets like India, Japan, and Singapore, opens doors for innovative drug discovery tools and collaborative development with global pharma leaders. For example, G7 CR Technologies in India is enabling AI-powered preclinical studies and molecule screening services for APAC pharma firms.
Asia-Pacific AI in Drug Discovery Market Revenue (USD Million), 2020-2035
The market experienced significant expansion from 2020 to 2025, with revenue rising from USD 120 million in 2020 to USD 340 million in 2025, driven by technological advancements and government support. This growth is expected to accelerate, reaching an estimated USD 2,890 million by 2035 at a CAGR of 21.8%. The chart data reflects a strong upward trajectory, underscoring heightened adoption of AI platforms by both established and emerging pharma companies. Key inflection points include post-pandemic investments in digital health and an influx of private capital to regional biotech startups, positioning Asia-Pacific as a major global hub for AI-driven drug discovery innovation.
Asia-Pacific AI Drug Discovery Market by Regions Share (%), 2025
China is expected to dominate the Asia-Pacific AI in drug discovery market in 2025, representing approximately 36% share, driven by its robust biotechnology sector and heavy investment in AI R&D. Japan holds the second largest share at 22%, underpinned by its sophisticated research infrastructure. India is fast emerging as a key market, accounting for 16%, thanks to a flourishing startup ecosystem and government initiatives. South Korea (14%) and Australia (12%) round out the top five, reflecting growing adoption of AI solutions and increased collaborative research activities with international pharma and AI tech businesses.
Recent Developments in Asia-Pacific AI Drug Discovery (Last 6 Months)
In March 2024, Insilico Medicine inaugurated a new AI research center in Shanghai in collaboration with WuXi AppTec. The center focuses on developing next-generation AI algorithms to improve drug candidate identification, especially for rare and complex diseases prevalent in Asia. The partnership aims to reduce drug discovery timelines and enhance regional innovation capacity, positioning Shanghai as a global AI drug discovery hub.
In April 2024, Takeda and Microsoft announced an agreement to co-develop an AI-driven platform for small molecule and biologic drug discovery in Japan. This initiative leverages Microsoft Azure’s high-performance cloud infrastructure and Takeda’s data-rich research pipeline, aiming to optimize prediction accuracy in early-stage drug identification and foster AI literacy across Takeda’s scientific teams.
In May 2024, Alibaba Cloud partnered with G7 CR Technologies to launch an AI-powered data analytics suite for drug discovery targeting mid-market and emerging biotech companies across Southeast Asia. The solution integrates multi-omics analysis and supports faster hypothesis generation, helping regional startups accelerate R&D cycles and enter global clinical pipelines more efficiently.
China, India, Japan, Taiwan, Vietnam, Philippines, Singapore, Australia, South Korea, Rest of APAC
Segments
By Type (Small Molecule Drug Discovery, Large Molecule Drug Discovery, Preclinical Drug Discovery, Drug Optimization & Repurposing, Target Identification & Validation, Others), By Application (Oncology, Neurology, Cardiovascular Diseases, Respiratory Diseases, Infectious Diseases, Others), By Distribution Channels (Direct Sales, Distributors, Online Channels, Value Added Resellers, System Integrators, Others), By Technology (Machine Learning, Deep Learning, Natural Language Processing, Computer Vision, Others, Hybrid Models), By Organization Size (Small, Medium, Large)
Press Releases